This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Creon After Pancreatic Surgery

This study has been completed.
Quintiles, Inc.
Data Map GmbH
Information provided by:
Abbott Identifier:
First received: September 25, 2007
Last updated: August 16, 2011
Last verified: August 2011
This study will provide efficacy data for Creon 25000 MMS in PS patients as well as long-term safety data. During the long-term treatment with Creon 25000 nutritional parameters will be assessed and correlated with CFA

Condition Intervention Phase
Pancreatic Insufficiency Drug: Creon Drug: Placebo Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Official Title: One Week Double-Blind, Randomized, Placebo-Controlled, Parallel-Group, Multi-Center Study With Creon® 25000 Minimicrospheres™ in Subjects With Pancreatic Exocrine Insufficiency After Pancreatic Surgery, Followed by an Open-Label Long-Term Extension of 1 Year

Resource links provided by NLM:

Further study details as provided by Abbott:

Primary Outcome Measures:
  • Change in CFA from baseline to the end of double blind treatment [ Time Frame: 7 days after baseline ]

Secondary Outcome Measures:
  • CNA, stool fat, stool weight, nutritional parameters, clinical symptomatology, SF-36, BMI [ Time Frame: 7 days after baseline, and end of open-label period (1 year of open label treatment) ]

Enrollment: 58
Study Start Date: April 2008
Study Completion Date: June 2011
Primary Completion Date: June 2011 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: 1 Drug: Creon
3 capsules Creon with 25000 lipase units per main meal (3 main meals) plus 2 capsules per snack (2-3 snacks)
Placebo Comparator: 2 Drug: Placebo


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria

Pancreatic exocrine insufficiency has to be proven (in medical history) by the following criteria:

  • Direct or indirect pancreatic function test (except stool fat excretion) and
  • Steatorrhoea: stool fat > 15 g/day (using van de Kamer method)
  • Proven chronic pancreatitis
  • Females of child-bearing potential must agree to continue using a medically acceptable method of birth control

Exclusion Criteria

  • Subjects in an unstable situation (catabolic) after pancreatic surgery
  • Ileus or acute abdomen
  • Current excessive intake of alcohol or drug abuse
  • Hypersensitivity vs porcine proteins / pancreatin
  • Subjects taking digestive enzyme preparations have to stop them before start of the run-in period
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00535756

Site Reference ID/Investigator# 45022
Ruse, Bulgaria, 7002
Site Reference ID/Investigator# 45020
Sofia, Bulgaria, 1233
Site Reference ID/Investigator# 45026
Greifswald, Germany, MV 17475
Site Reference ID/Investigator# 45025
Hamburg, Germany, 20246
Site Reference ID/Investigator# 45027
Heidelberg, Germany, 69120
Site Reference ID/Investigator# 45024
Munich, Germany, 81675
Site Reference ID/Investigator# 45126
Bekescsaba, Hungary, 5600
Site Reference ID/Investigator# 45121
Budaors, Hungary, 2040
Site Reference ID/Investigator# 45127
Dunaujvaros, Hungary, 2400
Site Reference ID/Investigator# 45115
Gyula, Hungary, 5700
Site Reference ID/Investigator# 45116
Sopron, Hungary, 9400
Site Reference ID/Investigator# 45114
Szeged, Hungary, 6720
Site Reference ID/Investigator# 45130
Bologna, Italy, 40138
Site Reference ID/Investigator# 45129
Padova, Italy, 35128
Site Reference ID/Investigator# 45128
Verona, Italy, 37126
Sponsors and Collaborators
Abbott Products
Quintiles, Inc.
Data Map GmbH
Study Director: Guenter Krause, MD Abbott Products
  More Information

Responsible Party: Gregor Eibes/Clinical Trial Manager, Abbott Products Identifier: NCT00535756     History of Changes
Other Study ID Numbers: S245.4.008
2005-004854-29 ( EudraCT Number )
Study First Received: September 25, 2007
Last Updated: August 16, 2011

Keywords provided by Abbott:
Pancreatic Exocrine Insufficiency After Pancreatic Surgery

Additional relevant MeSH terms:
Exocrine Pancreatic Insufficiency
Pancreatic Diseases
Digestive System Diseases
Gastrointestinal Agents processed this record on August 23, 2017